The company has a collaboration with Flavocure Biotech, Inc., for the identification and development of certain natural molecules. The company is actively pursuing some of the most virulent diseases, with a focus on SARS-Cov-2 (COVID-19).
In light of compelling scientific data, a panel of researchers have concluded that the drug Caflanone should be considered for clinical trials. This effort has been named ENDEAVOR-1 – Beating COVID-19.
The growing novel coronavirus, SARS-CoV-2, pandemic has resulted in over 4.6 million infections and 300,000 deaths as of May 20, 2020 according to statistics from the World Health Organization . Identification of effective antiviral agents to combat the SARS-CoV-2 is urgently needed.